CLINICAL_TRIALS
trial_result
· 2024-04-26
Clinical Trial Update: A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease [Phase 4]
Summary
A Phase 4 study evaluating TEPEZZA (teprotumumab) for chronic inactive thyroid eye disease has been completed, with results posted in April 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease | Phase 4 | Status: COMPLETED | Results posted: 2024-04-26